Journal
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Volume 92, Issue 4, Pages 698-708Publisher
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.14-0268
Keywords
-
Funding
- US Army Medical Research and Materiel Command (Fort Detrick, MD)
- GlaxoSmithKline Biologicals S.A. (Rixensart, Belgium)
Ask authors/readers for more resources
The immunogenicity and protective efficacy of a candidate tetravalent dengue virus purified inactivated vaccine (TDENV PIV) formulated with alum or an Adjuvant System (AS01, AS03 tested at three different dose levels, or AS04) was evaluated in a 0,1-month vaccination schedule in rhesus macaques. One month after dose 2, all adjuvanted formulations elicited robust and persisting neutralizing antibody titers against all four dengue virus serotypes. Most of the formulations tested prevented viremia after challenge, with the dengue serotype 1 and 2 virus strains administered at 40 and 32 weeks post-dose 2, respectively. This study shows that inactivated dengue vaccines, when formulated with alum or an Adjuvant System, are candidates for further development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available